In the SUMMIT trial, tirzepatide, a GLP‐1 RA and glucose‐dependent insulinotropic polypeptide receptor agonist, reduced the risk of the composite of CV death and worsening HF events (defined as hospitalization or need for urgent visit requiring intravenous therapy for HF, or intensification of oral diuretic therapy) compared with placebo in participants with HFpEF and obesity (HR, 0.62; 95% CI, 0.41–0.95; P = 0.026; Table4).103. This evidence concerns the gene GLP1R and hydrops fetalis.